Atopic Dermatitis

Pediatric patients with atopic dermatitis who were treated with Dupixent plus topical corticosteroids had significant reductions in itch and improved quality of life in a phase 3 trial, according to a press release.

Oral abrocitinib, in combination with topical therapy, was effective and well tolerated in the treatment of moderate to severe atopic dermatitis in adolescents, according to phase 3 study results.

Dupilumab led to significant improvements in self-reported sleep disturbance among patients with atopic dermatitis, according to study results presented during the European Academy of Allergy and Clinical Immunology Hybrid Congress.

Sleep disturbance appeared common among school-aged children with atopic dermatitis and may be associated with neuropsychiatric impairment, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Certain probiotic strains lowered the risk for developing atopic dermatitis when administered to pregnant women and infants, according to a systematic meta-analysis published in Pediatric Allergy and Immunology.

Upadacitinib showed superior efficacy to dupilumab after 16 weeks of treatment in atopic dermatitis, with higher levels of skin clearance and itch relief, according to a study.

Dupilumab was associated with a rapid onset of action in B and T cells that persisted through a year of therapy in patients with atopic dermatitis, according to a study.

Atopic dermatitis symptoms were improved in patients who received selected probiotic strains, according to a study.

Adult and adolescent patients with moderate to severe atopic dermatitis had improved symptoms with abrocitinib monotherapy, according to a study of patient-reported outcomes.

A 200 mg single-dose prefilled pen for Dupixent has been approved by the FDA for at-home use to treat certain patients with atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis, according to a company announcement.